# Dapagliflozin Evaluation on Atrial Fibrillation Patients Followed Cox Maze IV Procedure

> **NCT05816733** · PHASE4 · UNKNOWN · sponsor: **Kun Hua** · enrollment: 348 (estimated)

## Conditions studied

- Atrial Fibrillation Recurrence
- Cox Maze IV
- Atrial Fibrillation
- Patients With or Without Heart Failure and Diabetes

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05816733
- **Lead sponsor:** Kun Hua
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-01
- **Primary completion:** 2024-06-07
- **Final completion:** 2024-08-07
- **Target enrollment:** 348 (ESTIMATED)
- **Last updated:** 2023-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05816733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05816733, "Dapagliflozin Evaluation on Atrial Fibrillation Patients Followed Cox Maze IV Procedure". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05816733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*